A new concept enables the generation of cell microenvironments by microobject assembly at an water/air interface. As the orientation of 30 μm sized polymer cubes and their capillary force assembly are controlled by the surface wettability, which in turn can be modulated by coating the initially exposed surfaces with gold and self-assembled monolayers, unique niches in closely packed arrays of cubes with vertex up orientation can be realized. The random assembly of distinctly different cubes, prefunctionalized or surface-structured exclusively on their top surface, facilitates the parallel generation of different microenvironments in a combinatorial manner, which paves the way to future systematic structure-property relationship studies with cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/anie.201814076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review.
Expert Opin Ther Pat
December 2024
Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Introduction: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 () gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile.
Areas Covered: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024.
Late-Stage Tailoring Steps in the Biosynthesis of β-Rubromycin Involve Successive Terminal Oxidations, a Selective Hydroxyl Reduction, and Distinctive O-Methylations.
Org Lett
December 2024
Xiangya International Academy of Translational Medicine, Central South University, Changsha, Hunan 410013, China.
β-Rubromycin () has a unique O-methylated naphthoquinone moiety and is an efficient inhibitor of human telomerase. Through and investigations, we elucidated the biosynthetic tailoring steps of compound , which involve the carboxyl terminal via successive oxidizations by RubU and RubO1/RubO2, O-methylation of the carboxyl terminal by RubX, and reduction of C-3' hydroxyl by RubK. The final tautomerization of the naphthoquinone moiety is mediated by RubO, which anchors the transitional intermediate through O-methylation to form the naphthoquinone tautomer.
View Article and Find Full Text PDFPioneering integration of combinatorial chemistry and machine learning to accelerate the development of tailored LNPs for mRNA delivery.
Acta Pharm Sin B
November 2024
Department of Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041 China.
Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment.
J Exp Clin Cancer Res
November 2024
Aix-Marseille Univ, CNRS, INP, Institute of Neurophysiopathology UMR7051, Team Gliomagenesis and Microenvironment, Faculté des Sciences Médicales et Paramédicales - Secteur Timone, 27, Bd Jean Moulin, Marseille, 13005, France.
Glioblastoma (GBM), an incurable primary brain tumor, typically requires surgical intervention followed by chemoradiation; however, recurrences remain fatal. Our previous work demonstrated that a nanomedicine hydrogel (GemC-LNC) delays recurrence when administered post-surgery. However, tumor debulking also triggers time-dependent immune reactions that promote recurrence at the resection cavity borders.
View Article and Find Full Text PDFA Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML.
Cancer Med
November 2024
Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Background: Despite advances made in targeted biomarker-based therapy for acute myeloid leukemia (AML) treatment, remission is often short and followed by relapse and acquired resistance. Functional precision medicine (FPM) efforts have been shown to improve therapy selection guidance by incorporating comprehensive biological data to tailor individual treatment. However, effectively managing complex biological data, while also ensuring rapid conversion of actionable insights into clinical utility remains challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!